The DOI matches its Crossref record; 120 of the 120 references it cites were found in a registry or an index.
The challenge of drug resistance in cancer treatment: a current overview
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
Szklarczyk, D., Morris, J. H., Cook, H., Kuhn, M., Wyder, S., Simonovic, M., Santos, A., Doncheva, N. T., Roth, A., Bork, P., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw937 · Cited by 6,980
Nowell, P. C. (1976) · Science · doi:10.1126/science.959840 · Cited by 6,471
Cellular processing of platinum anticancer drugs
Wang, D., & Lippard, S. J. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1691 · Cited by 3,801
Targeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609
Cisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335
CpG islands and the regulation of transcription
Deaton, A. M., & Bird, A. (2011) · Genes & Development · doi:10.1101/gad.2037511 · Cited by 3,187
Greaves, M., & Maley, C. C. (2012) · Nature · doi:10.1038/nature10762 · Cited by 3,162
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925
p53 is required for radiation-induced apoptosis in mouse thymocytes
Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., & Jacks, T. (1993) · Nature · doi:10.1038/362847a0 · Cited by 2,864
Drug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805
Mechanisms of Cancer Drug Resistance
Gottesman, M. M. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103929 · Cited by 2,643
Drug resistance in cancer: An overview
Housman, G., Byler, S., Heerboth, S., Lapinska, K., Longacre, M., Snyder, N., & Sarkar, S. (2014) · Cancers · doi:10.3390/cancers6031769 · Cited by 2,463
Schinkel, A. H., Smit, J. J. M., van Tellingen, O., Beijnen, J. H., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., van der Valk, M. A., Robanus-Maandag, E. C., te Riele, H. P. J., et al. (1994) · Cell · doi:10.1016/0092-8674(94)90212-7 · Cited by 2,281
Thymocyte apoptosis induced by p53-dependent and independent pathways
Clarke, A. R., Purdie, C. A., Harrison, D. J., Morris, R. G., Bird, C. C., Hooper, M. L., & Wyllie, A. H. (1993) · Nature · doi:10.1038/362849a0 · Cited by 2,271
Purification and Characterization of Hypoxia-inducible Factor 1
Wang, G. L., & Semenza, G. L. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.3.1230 · Cited by 2,073
The Different Mechanisms of Cancer Drug Resistance: A Brief Review
Mansoori, B., Mohammadi, A., Davudian, S., Shirjang, S., & Baradaran, B. (2017) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2017.041 · Cited by 1,883
Cordon-Cardo, C., O'Brien, J. P., Casals, D., Rittman-Grauer, L., Biedler, J. L., Melamed, M. R., & Bertino, J. R. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.2.695 · Cited by 1,750
Hypoxia signalling in cancer and approaches to enforce tumour regression
Pouysségur, J., Dayan, F., & Mazure, N. M. (2006) · Nature · doi:10.1038/nature04871 · Cited by 1,676
The cell: a molecular approach
(1997) · Choice Reviews Online · doi:10.5860/choice.35-0264 · Cited by 1,445
DQIS Research Group (2026) · PubMed · doi:10.5281/zenodo.21937949 · Cited by 1,327
The cell. A molecular approach
Vella, F. (1998) · Biochemical Education · doi:10.1016/s0307-4412(98)00065-x · Cited by 1,189
P-glycoprotein: from genomics to mechanism
Ambudkar, S. V., Kimchi-Sarfaty, C., Sauna, Z. E., & Gottesman, M. M. (2003) · Oncogene · doi:10.1038/sj.onc.1206948 · Cited by 1,074
Intratumor Heterogeneity: Evolution through Space and Time
Swanton, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2217 · Cited by 931
The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux
Synold, T. W., Dussault, I., & Forman, B. M. (2001) · Nature Medicine · doi:10.1038/87912 · Cited by 840
(2002) · PubMed · Cited by 840
MGMT: its role in cancer aetiology and cancer therapeutics
Gerson, S. L. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1319 · Cited by 813
Tannock, I. F. (1968) · British Journal of Cancer · doi:10.1038/bjc.1968.34 · Cited by 763
Mechanisms of Taxol resistance related to microtubules
Orr, G. A., Verdier-Pinard, P., McDaid, H., & Horwitz, S. B. (2003) · Oncogene · doi:10.1038/sj.onc.1206934 · Cited by 727
Metronomic chemotherapy: new rationale for new directions
Pasquier, E., Kavallaris, M., & André, N. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.82 · Cited by 659
O'Hare, T., Eide, C. A., & Deininger, M. W. N. (2007) · Blood · doi:10.1182/blood-2007-03-066936 · Cited by 641
Dumontet, C., & Sikic, B. I. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.3.1061 · Cited by 574
The Role of ABC Transporters in Drug Resistance, Metabolism and Toxicity
Glavinas, H., Krajcsi, P., Cserepes, J., & Sarkadi, B. (2004) · Current Drug Delivery · doi:10.2174/1567201043480036 · Cited by 558
Dalton, W. S., Grogan, T. M., Meltzer, P. S., Scheper, R. J., Durie, B. G., Taylor, C. W., Miller, T. P., & Salmon, S. E. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.4.415 · Cited by 556
Campos, L., Guyotat, D., Archimbaud, E., Calmard-Oriol, P., Tsuruo, T., Troncy, J., Treille, D., & Fiere, D. (1992) · Blood · doi:10.1182/blood.v79.2.473.473 · Cited by 487
Fan, S., El‐Deiry, W. S., Bae, I., Freeman, J., Jondle, D., Bhatia, K. G., Fornace, A. J., MAGRATH, I. T., Kohn, K. W., & O'Connor, P. M. (1994) · PubMed · Cited by 454
Inhibition of the Multidrug Resistance P-Glycoprotein: Time for a Change of Strategy?
Callaghan, R., Luk, F., & Bebawy, M. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.056176 · Cited by 453
Shaked, Y., Henke, E., Roodhart, J. M. L., Mancuso, P., Langenberg, M. H. G., Colleoni, M., Daenen, L. G., Man, S., Xu, P., Emmenegger, U., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.08.001 · Cited by 440
Drug resistance in cancer: Principles of emergence and prevention
Komarova, N. L., & Wodarz, D. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501870102 · Cited by 414
Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity.
Xu, Y., & Villalona-Calero, M. A. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf337 · Cited by 413
Microtubule-associated protein tau: A marker of paclitaxel sensitivity in breast cancer
Rouzier, R., Rajan, R., Wagner, P., Hess, K. R., Gold, D. L., Stec, J., Ayers, M., Ross, J. S., Zhang, P., Buchholz, T. A., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408974102 · Cited by 413
DNA repair mechanisms in cancer development and therapy
Torgovnick, A., & Schumacher, B. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00157 · Cited by 396
Marie, J., Zittoun, R., & Sikic, B. (1991) · Blood · doi:10.1182/blood.v78.3.586.586 · Cited by 394
Epigenetic Resensitization to Platinum in Ovarian Cancer
Matei, D., Fang, F., Shen, C., Schilder, J., Arnold, A., Zeng, Y., Berry, W. A., Huang, T., & Nephew, K. P. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3909 · Cited by 390
ABCG2: determining its relevance in clinical drug resistance
Robey, R. W., Polgar, O., Deeken, J., To, K. W., & Bates, S. E. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9042-6 · Cited by 387
Miller, T. P., Grogan, T. M., Dalton, W. S., Spier, C. M., Scheper, R. J., & Salmon, S. E. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.1.17 · Cited by 384
Paclitaxel Resistance: Molecular Mechanisms and Pharmacologic Manipulation
Yusuf, R., Duan, Z., Lamendola, D., Penson, R., & Seiden, M. (2003) · Current Cancer Drug Targets · doi:10.2174/1568009033333754 · Cited by 354
Overview: ABC Transporters and Human Disease
Gottesman, M. M., & Ambudkar, S. V. (2001) · Journal of Bioenergetics and Biomembranes · doi:10.1023/a:1012866803188 · Cited by 350
Ross, D. D., Yang, W., Abruzzo, L. V., Dalton, W. S., Schneider, E., Lage, H., Dietel, M., Greenberger, L., Cole, S. P. C., & Doyle, L. A. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.5.429 · Cited by 350
Hazlehurst, L. A., Damiano, J. S., Buyuksal, I., Pledger, W. J., & Dalton, W. S. (2000) · Oncogene · doi:10.1038/sj.onc.1203782 · Cited by 344
Ceppi, P., Volante, M., Novello, S., Rapa, I., Danenberg, K. D., Danenberg, P. V., Cambieri, A., Selvaggi, G., Saviozzi, S., Calogero, R., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl300 · Cited by 323
Enhancement of chemotherapy by manipulation of tumour pH
Raghunand, N., He, X., Sluis, R. V., Mahoney, B., Baggett, B., Taylor, C. W., Paine-Murrieta, G., Roe, D., Bhujwalla, Z. M., & Gillies, R. J. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690455 · Cited by 316
Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance
Wilting, R. H., & Dannenberg, J.-H. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.01.008 · Cited by 303
Ceramide glycosylation potentiates cellular multidrug resistance
LIU, Y., HAN, T., GIULIANO, A. E., & CABOT, M. C. (2001) · The FASEB Journal · doi:10.1096/fj.00-0223com · Cited by 303
Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I.
Andoh, T., Ishii, K., Suzuki, Y., Ikegami, Y., Kusunoki, Y., Takemoto, Y., & Okada, K. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.16.5565 · Cited by 287
Zeller, C., Dai, W., Steele, N. L., Siddiq, A., Walley, A. J., Wilhelm-Benartzi, C. S. M., Rizzo, S., van der Zee, A., Plumb, J. A., & Brown, R. (2012) · Oncogene · doi:10.1038/onc.2011.611 · Cited by 285
Deffie, A. M., Batra, J. K., & Goldenberg, G. J. (1989) · PubMed · Cited by 261
Rice, G. C., Hoy, C., & Schimke, R. T. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.16.5978 · Cited by 249
Vaults Are Up-regulated in Multidrug-resistant Cancer Cell Lines
Kickhoefer, V. A., Rajavel, K. S., Scheffer, G. L., Dalton, W. S., Scheper, R. J., & Rome, L. H. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.15.8971 · Cited by 248
List, A., Spier, C., Grogan, T., Johnson, C., Roe, D., Greer, J., Wolff, S., Broxterman, H., Scheffer, G., Scheper, R., et al. (1996) · Blood · doi:10.1182/blood.v87.6.2464.bloodjournal8762464 · Cited by 238
Evolution of Resistance During Clonal Expansion
Iwasa, Y., Nowak, M. A., & Michor, F. (2006) · Genetics · doi:10.1534/genetics.105.049791 · Cited by 233
Cell kinetics and chemotherapy: a critical review.
Tannock, I. F. (1978) · PubMed · Cited by 223
Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance.
Bradshaw, D. M., & Arceci, R. J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.11.3674 · Cited by 223
Chen, Y. N., Mickley, L. A., Schwartz, A. M., Acton, E. M., Hwang, J. L., & Fojo, A. T. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)38781-2 · Cited by 221
Drug resistance to targeted therapies: Déjà vu all over again
Groenendijk, F. H., & Bernards, R. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.05.004 · Cited by 209
FOJO, T. (2007) · Drug Resistance Updates · doi:10.1016/j.drup.2007.02.002 · Cited by 191
Tumor acidity, ion trapping and chemotherapeutics
Raghunand, N., Mahoney, B. P., & Gillies, R. J. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(03)00468-4 · Cited by 182
Modulation of multidrug resistance: at the threshold.
Sikic, B. I. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.9.1629 · Cited by 182
Drug development in oncology: classical cytotoxics and molecularly targeted agents
Kummar, S., Gutierrez, M., Doroshow, J. H., & Murgo, A. J. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02713.x · Cited by 177
Limited Tissue Penetration of Taxanes: A Mechanism for Resistance in Solid Tumors
Kyle, A. H., Huxham, L. A., Yeoman, D. M., & Minchinton, A. I. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1941 · Cited by 172
Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance
Shukla, S., Chen, Z.-S., & Ambudkar, S. V. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.01.005 · Cited by 168
Mechanisms of Acquired Resistance to Targeted Cancer Therapies
Lackner, M. R., Wilson, T. R., & Settleman, J. (2012) · Future Oncology · doi:10.2217/fon.12.86 · Cited by 164
Clinical Studies with Modulators of Multidrug Resistance
Fisher, G. A., & Sikic, B. I. (1995) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(18)30099-6 · Cited by 163
Mahadevan, D., & List, A. F. (2004) · Blood · doi:10.1182/blood-2003-07-2490 · Cited by 161
Multidrug Resistance/P-Glycoprotein and Breast Cancer: Review and Meta-Analysis
Clarke, R., Leonessa, F., & Trock, B. (2005) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.09.009 · Cited by 159
The cancer stem-cell signaling network and resistance to therapy
Carnero, A., Garcia‐Mayea, Y., Mir, C., Lorente, J., Rubio, I. T., & LLeonart, M. E. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.07.001 · Cited by 159
TUMOUR CELL PROLIFERATION IN RELATION TO THE VASCULATURE
Hirst, D. G., & Denekamp, J. (1979) · Cell Proliferation · doi:10.1111/j.1365-2184.1979.tb00111.x · Cited by 154
Bhatla, T., Wang, J., Morrison, D. J., Raetz, E. A., Burke, M. J., Brown, P. A., & Carroll, W. L. (2012) · Blood · doi:10.1182/blood-2012-01-401687 · Cited by 145
Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy
Huang, Y. S. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9050-6 · Cited by 144
Ljungkvist, A. S. E., Bussink, J., Rijken, P. F. J. W., Kaanders, J. H. A. M., van der Kogel, A. J., & Denekamp, J. (2002) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(02)02938-3 · Cited by 144
Targeted cancer therapy – Are the days of systemic chemotherapy numbered?
Joo, W. D., Visintin, I., & Mor, G. (2013) · Maturitas · doi:10.1016/j.maturitas.2013.09.008 · Cited by 143
A stochastic model for the origin and treatment of tumors containing drug-resistant cells
Coldman, A. J., & Goldie, J. H. (1986) · Bulletin of Mathematical Biology · doi:10.1007/bf02459682 · Cited by 143
Matsumoto, S., Batra, S., Saito, K., Yasui, H., Choudhuri, R., Gadisetti, C., Subramanian, S., Devasahayam, N., Munasinghe, J., Mitchell, J. B., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-2025 · Cited by 137
Pharmacologic approaches to reversing multidrug resistance.
Sikic, B. I. (1997) · PubMed · Cited by 131
The Role of Half-Transporters in Multidrug Resistance
Bates, S. E., Robey, R. W., Miyake, K., Rao, K. V., Ross, D. D., & Litman, T. (2001) · Journal of Bioenergetics and Biomembranes · doi:10.1023/a:1012879205914 · Cited by 130
Judah Folkman, a pioneer in the study of angiogenesis
Ribatti, D. (2008) · Angiogenesis · doi:10.1007/s10456-008-9092-6 · Cited by 129
DNA repair in resistance to alkylating anticancer drugs
Kaina, B., & Christmann, M. (2002) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp40354 · Cited by 117
Shain, K. H., & Dalton, W. S. (2001) · PubMed · Cited by 117
Continuous Infusion or Bolus Injection in Cancer Chemotherapy
Carlson, R. W., & Sikic, B. I. (1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-99-6-823 · Cited by 114
Dumontet, C., Durán, G. E., Steger, K. A., Beketić-Orešković, L., & Sikic, B. I. (1996) · PubMed · Cited by 111
Chen, K. G., Jaffrézou, J., Fleming, W., Durán, G. E., & Sikic, B. I. (1994) · PubMed · Cited by 94
Determinants of resistance to chemotherapy and ionizing radiation in breast cancer stem cells
Pavlopoulou, A., Oktay, Y., Vougas, K. N., Louka, M. A., Vorgias, C. E., & Georgakilas, A. G. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.07.018 · Cited by 93
Self-citationRice, G. C., Ling, V. W. T., & Schimke, R. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.24.9261 · Cited by 90
Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine
Benzekry, S., Pasquier, E., Barbolosi, D., Lacarelle, B., Barlési, F., André, N., & Ciccolini, J. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.09.002 · Cited by 90
Hypoxic cells as specific drug targets for chemotherapy.
Ka, K. (1987) · PubMed · Cited by 88
Chang, X.-B. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9041-7 · Cited by 87
Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma
Issa, M. E., Takhsha, F. S., Chirumamilla, C. S., Perez-Novo, C. A., Berghe, W. V., & Cuendet, M. (2017) · Clinical Epigenetics · doi:10.1186/s13148-017-0319-5 · Cited by 84
Wagner, P., Wang, B., Clark, E. A., Lee, H., Rouzier, R., & Pusztai, L. (2005) · Cell Cycle · doi:10.4161/cc.4.9.2038 · Cited by 80
Beketić-Orešković, L., Durán, G. E., Chen, K. G., Dumontet, C., & Sikic, B. I. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.21.1593 · Cited by 79
Defeating drug resistance in cancer.
Gottesman, M. M., Ludwig, J. A., Xia, D., & Szakács, G. (2006) · PubMed · Cited by 76
The Evolution of Two Mutations During Clonal Expansion
Haeno, H., Iwasa, Y., & Michor, F. (2007) · Genetics · doi:10.1534/genetics.107.078915 · Cited by 75
Tumour heterogeneity and drug resistance: Personalising cancer medicine through functional genomics
Lee, A. J. X., & Swanton, C. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.12.008 · Cited by 71
A generalized Luria–Delbrück model
Dewanji, A., Luebeck, E. G., & Moolgavkar, S. H. (2005) · Mathematical Biosciences · doi:10.1016/j.mbs.2005.07.003 · Cited by 64
Wang, Y. C., Juric, D., Francisco, B. S., Yu, R., Durán, G. E., Chen, K. G., Chen, X., & Sikic, B. I. (2005) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20300 · Cited by 61
Prodding the Beast: Assessing the Impact of Treatment-Induced Metastasis
Ebos, J. M. L. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0308 · Cited by 60
An explicit representation of the Luria-Delbrück distribution
Angerer, W. P. (2001) · Journal of Mathematical Biology · doi:10.1007/s002850000053 · Cited by 53
Chen, K. G., Wang, Y. C., Schaner, M. E., Francisco, B. S., Durán, G. E., Juric, D., Huff, L. M., Padilla‐Nash, H. M., Ried, T., Fojo, T., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4133 · Cited by 53
Cellular adaptation to drug exposure: evolution of the drug-resistant phenotype.
Matsumoto, Y., Takano, H., & Fojo, T. (1997) · PubMed · Cited by 50
Tumor cell resistance to DNA topoisomerase II inhibitors: new developments
Beck, W. T., Morgan, S. E., Mo, Y.-Y., & Bhat, U. G. (1999) · Drug Resistance Updates · doi:10.1054/drup.1999.0110 · Cited by 37
Burg, D., Wielinga, P. R., Zelcer, N., SAEKI, T., Mulder, G. J., & Borst, P. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.5.1160 · Cited by 36
Mutation Rates and Mechanisms of Resistance to Etoposide Determined From Flucattion Analysis
Jaffrézou, J., Chen, K. G., Durán, G. E., Js, K., & Sikic, B. I. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.15.1152 · Cited by 35
The Genetic Basis of Resistance to Cancer Chemotherapy
Woodhouse, J., & Ferry, D. R. (1995) · Annals of Medicine · doi:10.3109/07853899509031953 · Cited by 35
Epigenetic Targeting Therapies to Overcome Chemotherapy Resistance
Balch, C., & Nephew, K. P. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-9967-2_14 · Cited by 31
Dose and outcome: The hurdle of neutropenia (Review)
Marangolo, M., Bengala, C., Conte, P., Danova, M., Pronzato, P., Rosti, G., & Sagrada, P. (2006) · Oncology Reports · doi:10.3892/or.16.2.233 · Cited by 28
Clinical Resistance to Antimetabolites
Spears, C. P. (1995) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(18)30101-1 · Cited by 24
On the role of endothelial progenitor cells in tumor neovascularization
Komarova, N. L., & Mironov, V. (2005) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2005.01.014 · Cited by 23
“Drug resistance associated membrane proteins”
Sherlach, K. S., & Roepe, P. D. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00108 · Cited by 23
Capranico, G., Isabella, P. D., Castelli, C., Supino, R., Parmiani, G., & Zunino, F. (1989) · British Journal of Cancer · doi:10.1038/bjc.1989.141 · Cited by 14
Chemotherapy administration: Doses, infusions and choice of schedule
Cassidy, J. (1994) · Annals of Oncology · doi:10.1093/annonc/5.suppl_4.s25 · Cited by 9
Cowan (2001) · doi:10.1002/1097-0215(20010101)91:1<120::aid-ijc1021>3.0.co;2-y
Cited by
Polymeric micelles in cancer therapy: State of the art
Ghosh, B., & Biswas, S. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.02.016 · Cited by 546
Unveiling the mechanisms and challenges of cancer drug resistance
Khan, S. U., Fatima, K., Aisha, S., & Malik, F. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01302-1 · Cited by 417
Overcoming cancer chemotherapy resistance by the induction of ferroptosis
Wang, Y., Wu, X., Ren, Z., Li, Y., Zou, W., Chen, J., & Wang, H. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100916 · Cited by 361
Chemoresistance mechanisms of breast cancer and their countermeasures
Ji, X., Lu, Y., Tian, H., Meng, X., Wei, M., & Cho, W. C. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108800 · Cited by 340
Polytherapy and Targeted Cancer Drug Resistance
Chatterjee, N., & Bivona, T. G. (2019) · Trends in Cancer · doi:10.1016/j.trecan.2019.02.003 · Cited by 270
Metadata
- Authors
- Nikolaou, M., Pavlopoulou, A., Georgakilas, A. G., & Kyrodimos, E.
- Venue
- Clinical & Experimental Metastasis
- Published
- 2018-04
- Volume
- 35
- Issue
- 4
- Pages
- 309-318
- ISSN
- 0262-0898 (ISSN-L)
- 1573-7276
- OpenAlex
- W2803908182
- Cited by
- 600
- References
- 120
- FWCI
- 16.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.